Human medicines European public assessment report (EPAR): Caprelsa, vandetanib, Date of authorisation: 16/02/2012, Revision: 29, Status: Authorised

Submitted by Anonymous (not verified) on 25 June 2025 - 11:09

Human medicines European public assessment report (EPAR): Caprelsa, vandetanib, Date of authorisation: 16/02/2012, Revision: 29, Status: Authorised

Opinion/decision on a Paediatric investigation plan (PIP): Recarbrio, imipenem monohydrate,cilastatin sodium,relebactam (MK-7655A), decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infections and infestat

Submitted by Anonymous (not verified) on 25 June 2025 - 10:35

Opinion/decision on a Paediatric investigation plan (PIP): Recarbrio, imipenem monohydrate,cilastatin sodium,relebactam (MK-7655A), decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infections and infestations, PIP number: P/0190/2024

Opinion/decision on a Paediatric investigation plan (PIP): Steglatro, Ertugliflozin, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Metabolism and nutrition disorders, PIP number: P/0189/2024

Submitted by Anonymous (not verified) on 25 June 2025 - 10:17

Opinion/decision on a Paediatric investigation plan (PIP): Steglatro, Ertugliflozin, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Metabolism and nutrition disorders, PIP number: P/0189/2024

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More
randomness